Incyte Reports Topline Data from P-III (inMIND) Trial of Monjuvi to Treat Relapsed or Refractory FL
Shots:
- The P-III (inMIND) trail assessing efficacy and safety of Monjuvi (tafasitamab) + rituximab + lenalidomide vs. PBO + rituximab + lenalidomide via. IV
- Study met its 1EP: PFS in FL; 2EPs: PFS in the overall population and the positron-emission tomography-CRR in the FDG-avid FL population. Safety concerns were not observed
- Based on these results, Incyte planning to file sBLA to treat min. one prior systemic anti-CD20 immuntx. or chemo-immuntx. failed FL patients by H2’24
Ref: Incyte | Image: Incyte
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
